Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.66 |
| ▸ | BRAF | P15056 | 10/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.66 |
| ▸ | TNNI3K | Q59H18 | 10/20 | 0.66 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.63 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.60 |
| ▸ | LDLR | P01130 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22528864 | 0.89 | KDR (0.66) | KDRBRAFMAPK14TNNI3KNR2E1 | |
| SCHEMBL10301397 | 0.84 | NR2E1 (0.66) | KDRBRAFMAPK14TNNI3KNR2E1 | |
| SCHEMBL12972384 | 0.84 | NR2E1 (0.54) | KDRBRAFMAPK14TNNI3KNR2E1 | |
| SCHEMBL5452552 | 0.83 | NR2E1 (0.51) | KDRBRAFMAPK14TNNI3KNR2E1 | |
| SCHEMBL2840607 | 0.80 | KDR (0.56) | KDRBRAFMAPK14TNNI3KNR2E1 | |
| SCHEMBL2845565 | 0.80 | KDR (0.66) | KDRBRAFMAPK14TNNI3KNR2E1 | |
| SCHEMBL3183280 | 0.80 | KDR (1.00) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL13261062 | 0.79 | NR2E1 (1.00) | NR2E1 | |
| SCHEMBL22528887 | 0.76 | KDR (0.72) | KDRBRAFMAPK14TNNI3KMAP4K2 | |
| SCHEMBL10301398 | 0.75 | NR2E1 (0.63) | KDRBRAFNR2E1MAP4K2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3730483-B1 | CLASS OF PYRIMIDINE DERIVATIVE KINASE INHIBITORS | HEFEI INST PHYSICAL SCI CAS (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11602534-B2 | Pyrimidine derivative kinase inhibitors | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-03-14 | — | — | US | disclosed |
| EP-3730483-A1 | CLASS OF PYRIMIDINE DERIVATIVE KINASE INHIBITORS | Hefei Institutes of Physical Science, Chinese Academy of Sciences (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-20200323850-A1 | PYRIMIDINE DERIVATIVE KINASE INHIBITORS | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323850-A1 | PYRIMIDINE DERIVATIVE KINASE INHIBITORS | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (US) | 2020-10-15 | — | — | US | disclosed |
| CN-108368060-B | Pyrimidine derivative kinase inhibitors | 中国科学院合肥物质科学研究院 | 2020-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323850-A1 | PYRIMIDINE DERIVATIVE KINASE INHIBITORS | FLT3, PDGFRB, PDGFRA | KDR 40/4885BRAF 14/4885MAPK14 356/4885 |
| US-11602534-B2 | Pyrimidine derivative kinase inhibitors | FLT3, PDGFRB, PDGFRA | KDR 40/4885BRAF 14/4885MAPK14 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.